|RXi Pharmaceuticals Corporation|
257 Simarano Drive
United States - Map
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma. The companys preclinical program includes the development of products for ocular indications with RXI-109, including retinal and corneal scarring. Its discovery stage development programs include a dermatology franchise for the discovery of collagenase and tyrosinase targets for its RNAi platform; and ophthalmology franchise, a program for the discovery of sd-rxRNA compounds for oncology indications, including retinoblastoma. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
|Dr. Geert Cauwenbergh Ph.D., Med.Sc.,
Chief Exec. Officer, Pres, Director and Member of Corp. Governance Committee
|Dr. Pamela A. Pavco Ph.D.,
Chief Devel. Officer
|Ms. Caitlin Kontulis ,
Principal Accounting Officer, Controller and Sec.
|Dr. Karen Bulock Ph.D.,
VP of Research
|Dr. Lyn Libertine M.D.,
VP of Medical Affairs & Safety Assessment
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|